IRTC vs. PRCT, AXNX, TNDM, NARI, ICUI, IART, MMSI, ATEC, HAE, and LMAT
Should you be buying iRhythm Technologies stock or one of its competitors? The main competitors of iRhythm Technologies include PROCEPT BioRobotics (PRCT), Axonics (AXNX), Tandem Diabetes Care (TNDM), Inari Medical (NARI), ICU Medical (ICUI), Integra LifeSciences (IART), Merit Medical Systems (MMSI), Alphatec (ATEC), Haemonetics (HAE), and LeMaitre Vascular (LMAT). These companies are all part of the "surgical & medical instruments" industry.
iRhythm Technologies (NASDAQ:IRTC) and PROCEPT BioRobotics (NASDAQ:PRCT) are both mid-cap medical companies, but which is the better stock? We will contrast the two companies based on the strength of their valuation, risk, earnings, institutional ownership, media sentiment, profitability, community ranking, dividends and analyst recommendations.
In the previous week, PROCEPT BioRobotics had 11 more articles in the media than iRhythm Technologies. MarketBeat recorded 16 mentions for PROCEPT BioRobotics and 5 mentions for iRhythm Technologies. iRhythm Technologies' average media sentiment score of 0.70 beat PROCEPT BioRobotics' score of 0.46 indicating that iRhythm Technologies is being referred to more favorably in the media.
89.5% of PROCEPT BioRobotics shares are held by institutional investors. 0.7% of iRhythm Technologies shares are held by company insiders. Comparatively, 17.4% of PROCEPT BioRobotics shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.
iRhythm Technologies currently has a consensus price target of $134.00, indicating a potential upside of 34.19%. PROCEPT BioRobotics has a consensus price target of $61.20, indicating a potential downside of 3.70%. Given iRhythm Technologies' higher probable upside, analysts plainly believe iRhythm Technologies is more favorable than PROCEPT BioRobotics.
iRhythm Technologies has a net margin of -25.33% compared to PROCEPT BioRobotics' net margin of -66.12%. PROCEPT BioRobotics' return on equity of -41.35% beat iRhythm Technologies' return on equity.
iRhythm Technologies received 361 more outperform votes than PROCEPT BioRobotics when rated by MarketBeat users. Likewise, 66.04% of users gave iRhythm Technologies an outperform vote while only 62.22% of users gave PROCEPT BioRobotics an outperform vote.
iRhythm Technologies has a beta of 1.31, meaning that its stock price is 31% more volatile than the S&P 500. Comparatively, PROCEPT BioRobotics has a beta of 0.95, meaning that its stock price is 5% less volatile than the S&P 500.
PROCEPT BioRobotics has lower revenue, but higher earnings than iRhythm Technologies. PROCEPT BioRobotics is trading at a lower price-to-earnings ratio than iRhythm Technologies, indicating that it is currently the more affordable of the two stocks.
Summary
iRhythm Technologies beats PROCEPT BioRobotics on 9 of the 16 factors compared between the two stocks.
Get iRhythm Technologies News Delivered to You Automatically
Sign up to receive the latest news and ratings for IRTC and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding IRTC and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
iRhythm Technologies Competitors List
Related Companies and Tools
